Telomir Pharmaceuticals, Inc.
TELO evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for TELO—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · TELO
Telomir Pharmaceuticals, Inc. is a pre-revenue biopharmaceutical company focused on developing Telomir-Zn, a small-molecule candidate targeting telomere biology and metal modulation for oncology and age-related diseases, currently in Phase 1/2 clinical trials.
Key risk: Clinical development risk
BioSniper Score
Based on 4 of 6 signals
Market Cap
$78.4M
Cash Runway
—
Lead Asset
telomir-1 (Phase 1/Phase 2)
Next Catalyst
Phase2_Start · Oct 1, 2026Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 1 clinical trial · 1 catalyst for Telomir Pharmaceuticals, Inc..
Telomir Pharmaceuticals, Inc. is a pre-revenue biopharmaceutical company focused on developing Telomir-Zn, a small-molecule candidate targeting telomere biology and metal modulation for oncology and age-related diseases, currently in Phase 1/2 clinical trials.
- Telomir Pharmaceuticals is developing Telomir-Zn (formerly Telomir-1), a small molecule that modulates intracellular metals and targets telomere-related biology for oncology and age-related indications [sec · filed 2026-04-30].
- The company completed a merger with TELI Pharmaceuticals, Inc. on April 22, 2026, acquiring exclusive worldwide intellectual property rights to Telomir-Zn [sec_mda · as of 2026-08-13].
- As of June 30, 2026, the company reported shareholders' equity of $5.9M and a net loss of $1.7M for the quarter ended June 30, 2026 [sec].
- The Phase 2 portion of the ongoing Phase 1/2 study is designed to evaluate objective response rate (ORR) as the primary efficacy endpoint, with secondary endpoints including duration of response, progression-free survival, and overall survival [sec · filed 2026-04-30].
- Preclinical studies in non-rodent models (dogs) showed no test-article-related changes in blood pressure, heart rate, ECG, or body temperature after oral administration of Telomir-1 [sec · filed 2025-12-17].
What works
- Telomir-Zn has demonstrated statistically significant reductions in tumor growth and metastasis in zebrafish xenograft models of triple-negative breast cancer (TNBC) [sec · filed 2026-02-17].
- The company has completed IND-enabling GLP studies and anticipates submitting an IND application in the first quarter of 2026 [sec · filed 2026-02-17].
- Preclinical safety data in non-rodent studies showed no adverse effects on cardiovascular parameters, supporting continued clinical development [sec · filed 2025-12-17].
What to weigh
- The company has a history of net losses, with a net loss of $2.7 million for the six months ended June 30, 2026 [sec_mda · as of 2026-08-13].
- Telomir Pharmaceuticals is a pre-revenue company with no approved products and depends on successful clinical development and regulatory approval [sec_mda · as of 2026-08-13].
- The company faces significant risks related to preclinical and clinical development, including the initiation, timing, progress, and results of clinical trials [sec · filed 2026-08-10].
From the filings
Quoted directly from source documents.
The Phase 2 portion of the study uses objective response rate as the primary endpoint.
“The Phase 2 portion of the study is designed to evaluate preliminary efficacy, with the objective response rate (ORR) as the primary endpoint”
SEC filings · April 30, 2026
Telomir-1 showed no cardiovascular effects in non-rodent studies.
“In non-rodent studies, including in dogs, no test-article-related changes in blood pressure, heart rate, electrocardiogram (ECG) parameters, or body temperature were observed following oral administration of Telomir-1.”
SEC filings · December 17, 2025
The company reported a net loss of $2.7 million for the first half of 2026.
“We had net losses of $2.7 million and $7.3 million for the six months ended June 30, 2026 and 2025, respectively.”
SEC MD&A · August 13, 2026
The merger with TELI Pharmaceuticals closed on April 22, 2026.
“On April 22, 2026, the Company consummated its previously announced merger with TELI Pharmaceuticals, Inc., a related party private company”
SEC MD&A · August 13, 2026
Catalyst timeline
- 2026-10-01 · Phase 2 Start — The company plans to initiate the Phase 2 portion of its Phase 1/2 study evaluating Telomir-Zn, with objective response rate as the primary endpoint.
Risks & what to watch (4)›
Key risks
- Clinical development risk — The company's success depends on the safety and efficacy of Telomir-Zn in ongoing and future clinical trials [sec · filed 2026-08-10].
- Financial sustainability — The company has a history of net losses and may need additional funding to support operations and clinical development [sec_mda · as of 2026-08-13].
- Regulatory approval uncertainty — Telomir-Zn has not received regulatory approval; the company must successfully complete clinical trials and obtain marketing authorization [sec · filed 2026-08-10].
- Dependence on single product — The company's pipeline is heavily focused on Telomir-Zn, with limited diversification across other programs [sec_mda · as of 2026-08-13].
What to watch
- Initiation and enrollment of the Phase 2 portion of the Phase 1/2 study for Telomir-Zn [sec · filed 2026-04-30].
- Submission of an Investigational New Drug (IND) application, anticipated in the first quarter of 2026 [sec · filed 2026-02-17].
- Presentation of preclinical data at oncology-focused scientific conferences [sec · filed 2025-12-17].
- Financial updates and cash runway disclosures in future SEC filings [sec_mda · as of 2026-08-13].
Sources: SEC filings · SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run Telomir Pharmaceuticals, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Telomir Pharmaceuticals, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.07 · 0% dilution
Lead: Phase 1/Phase 2
1 candidate
1 upcoming, next in ~32d
No insider transactions in the last 180 days
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
25
Total value held
$4.1M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 1,990,746 | $2.6M |
| blackrock, inc. | 289,198 | $376K |
| geode capital management, llc | 249,086 | $324K |
| vanguard fiduciary trust co | 135,541 | $176K |
| millennium management llc | 129,060 | $168K |
| state street corp | 58,600 | $76K |
| bank of new york mellon corp | 51,454 | $67K |
| northern trust corp | 41,844 | $54K |
| xtx topco ltd | 36,061 | $47K |
| osaic holdings, inc. | 35,795 | $47K |
Showing top 10 of 25 institutional holders of Telomir Pharmaceuticals, Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 21, 2026- % of float
- 5.9%
- Days to cover
- 15.1
- Shares short
- 1,225,205
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
TELO short interestGovernance
Frequently asked questions
What is the AI investment thesis for Telomir Pharmaceuticals, Inc.?
Telomir Pharmaceuticals, Inc. is a pre-revenue biopharmaceutical company focused on developing Telomir-Zn, a small-molecule candidate targeting telomere biology and metal modulation for oncology and age-related diseases, currently in Phase 1/2 clinical trials.
What is Telomir Pharmaceuticals, Inc.'s lead drug candidate?
Telomir Pharmaceuticals, Inc.'s most advanced tracked candidate is telomir-1 (Phase 1/Phase 2) for Triple-Negative Breast Cancer (TNBC).
What is Telomir Pharmaceuticals, Inc.'s next catalyst?
Telomir Pharmaceuticals, Inc.'s next tracked catalyst is a Phase2_Start event — "Phase 2 Start: A First-in-Human (FIH), Phase I/II, Multicenter, Open-Label Study to Evaluate the Safety, Tolerabili" — expected October 1, 2026.
Who is the CEO of Telomir Pharmaceuticals, Inc.?
Mr. Erez Aminov is the chief executive officer of Telomir Pharmaceuticals, Inc. (TELO).
Where is Telomir Pharmaceuticals, Inc. headquartered?
Telomir Pharmaceuticals, Inc. (TELO) is headquartered in Miami, FL, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.